Article
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Lung cancer (Amsterdam, Netherlands) - 1 Mar 2011
Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T
Abstract excerpt
Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers (NSCLC) obtaining objective response when treated with gefitinib harbour activating mutations in the EGFR gene. Consequently, EGFR mutation has been widely studied, together with other molecular characteristics, as a potential...
Topics
- Antineoplastic Agents
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
- Clinical Trials, Phase III as Topic
- ErbB Receptors
- Gefitinib
- Humans
- Lung Neoplasms
- Mutation
- Prognosis